Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA Siren Biotechnology reveals SRN-101 as lead asset for high-grade gliomas with both Orphan Drug and Rare Pediatric Disease Designations from the FDA

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM) Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)